Angiotensin type 1 receptor antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Angiotensin type 1 receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Angiotensin type 1 receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Angiotensin type 1 receptor antagonists: Overview
Angiotensin II receptor blockers (ARBs), formally angiotensin II receptor type 1 (AT1) antagonists, also known as angiotensin receptor blockers, angiotensin II receptor antagonists, or AT1 receptor antagonists, are a group of pharmaceuticals that bind to and inhibit the angiotensin II receptor type 1 (AT1) and thereby block the arteriolar contraction and sodium retention effects of renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They selectively block the activation of the AT1 receptor, preventing the binding of angiotensin II compared to ACE inhibitors.
Report Highlights
This segment of the Angiotensin type 1 receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Angiotensin type 1 receptor antagonists Emerging Drugs
Further product details are provided in the report……..
Angiotensin type 1 receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Angiotensin type 1 receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Angiotensin type 1 receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Angiotensin type 1 receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angiotensin type 1 receptor antagonists drugs.
Angiotensin type 1 receptor antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Angiotensin type 1 receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Angiotensin type 1 receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Angiotensin type 1 receptor antagonists: Overview
Angiotensin II receptor blockers (ARBs), formally angiotensin II receptor type 1 (AT1) antagonists, also known as angiotensin receptor blockers, angiotensin II receptor antagonists, or AT1 receptor antagonists, are a group of pharmaceuticals that bind to and inhibit the angiotensin II receptor type 1 (AT1) and thereby block the arteriolar contraction and sodium retention effects of renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They selectively block the activation of the AT1 receptor, preventing the binding of angiotensin II compared to ACE inhibitors.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Angiotensin type 1 receptor antagonists R&D. The therapies under development are focused on novel approaches for Angiotensin type 1 receptor antagonists.
This segment of the Angiotensin type 1 receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Angiotensin type 1 receptor antagonists Emerging Drugs
- TRV027: Trevena
- Sparsentan: Travere Therapeutics
Further product details are provided in the report……..
Angiotensin type 1 receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Angiotensin type 1 receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Angiotensin type 1 receptor antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Angiotensin type 1 receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Angiotensin type 1 receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angiotensin type 1 receptor antagonists drugs.
Angiotensin type 1 receptor antagonists Report Insights
- Angiotensin type 1 receptor antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Angiotensin type 1 receptor antagonists drugs?
- How many Angiotensin type 1 receptor antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Angiotensin type 1 receptor antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angiotensin type 1 receptor antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Angiotensin type 1 receptor antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Trevena
- Travere Therapeutics
- Hanmi Pharmaceutical
- ARKAY Therapeutics
- Novartis
- Dimerix Bioscience
- Autotelic Bio
- LG Chem
- Boryung Pharmaceutical
- TRV027
- Sparsentan
- HCP 1701
- RK-01
- Enrest
- DMX-200
- ATB-101
- EV-81
- BKC 005
Introduction
Executive Summary
Angiotensin type 1 receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Angiotensin type 1 receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Sparsentan: Travere Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DMX-200: Dimerix Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ATB-101: Autotelic Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BKC 005: Boryung Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Angiotensin type 1 receptor antagonists Key Companies
Angiotensin type 1 receptor antagonists Key Products
Angiotensin type 1 receptor antagonists- Unmet Needs
Angiotensin type 1 receptor antagonists- Market Drivers and Barriers
Angiotensin type 1 receptor antagonists- Future Perspectives and Conclusion
Angiotensin type 1 receptor antagonists Analyst Views
Angiotensin type 1 receptor antagonists Key Companies
Appendix
Executive Summary
Angiotensin type 1 receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Angiotensin type 1 receptor antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Sparsentan: Travere Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
DMX-200: Dimerix Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ATB-101: Autotelic Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BKC 005: Boryung Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Angiotensin type 1 receptor antagonists Key Companies
Angiotensin type 1 receptor antagonists Key Products
Angiotensin type 1 receptor antagonists- Unmet Needs
Angiotensin type 1 receptor antagonists- Market Drivers and Barriers
Angiotensin type 1 receptor antagonists- Future Perspectives and Conclusion
Angiotensin type 1 receptor antagonists Analyst Views
Angiotensin type 1 receptor antagonists Key Companies
Appendix